Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention : insights from the AFCAS registry by M. Proietti et al.
Vol.:(0123456789) 
Clin Res Cardiol 
DOI 10.1007/s00392-016-1071-0
ORIGINAL PAPER
Synergic impact of oral anticoagulation control and renal 
function in determining major adverse events in atrial fibrillation 
patients undergoing percutaneous coronary intervention: insights 
from the AFCAS registry
Marco Proietti1 · K. E. Juhani Airaksinen2 · Andrea Rubboli3 · Axel Schlitt4 · 
Tuomas Kiviniemi5 · Pasi P. Karjalainen6 · Gregory Y. H. Lip1,7 · On behalf of the 
AFCAS Study Group
Received: 13 October 2016 / Accepted: 21 December 2016 
© The Author(s) 2017. This article is published with open access at Springerlink.com
Results Of the whole cohort, 448 were eligible for this 
post-hoc analysis. Of these, 27.9% had TTR <65%only 
(Group I), 19.2% had CrCl <60  ml/min only (Group II), 
while 13.8% had both conditions (Group III). At follow-
up, patients in Group III had a higher rate of major adverse 
cardiovascular and cerebrovascular events (MACCE) 
(p = 0.007), while patients in Groups I and III had higher 
rates of major bleeding. Kaplan–Meier analyses showed 
that patients in Group III had higher risk for MACCE 
(LogRank: 14.406, p = 0.003), while Group I and Group 
III patients had higher risk for major bleeding (LogRank: 
12.290, p = 0.006). On Cox regression, presence of 
both conditions independently increased MACCE risk 
(p = 0.001), while TTR <65% alone and the presence of 
both conditions were independently associated with major 
bleeding (p = 0.004 and p = 0.028, respectively).
Conclusions There was a synergic impact of oral antico-
agulation control and renal function in determining major 
adverse events in AF patients undergoing PCI-S. Use of 
poor anticoagulation control and impaired renal function 
in combination would help identify AF patients undergoing 
PCI-S at risk for MACCE and/or major bleeding.
Keywords Atrial fibrillation · Percutaneous coronary 
intervention · Quality of anticoagulation control · Renal 
impairment · Outcomes
Introduction
Atrial fibrillation (AF) is associated with a significant 
increase in thromboembolic and death risk [1, 2]. Oral anti-
coagulant (OAC) therapy reduces major adverse coronary 
and cerebrovascular events (MACCE) in patients with AF 
Abstract 
Background In patients with atrial fibrillation (AF), 
quality of oral anticoagulation control as well as impaired 
renal function are associated with adverse outcomes. Our 
objective was to analyze if there was a synergistic impact 
of these factors in determining adverse outcomes in AF 
patients undergoing percutaneous coronary intervention 
and stent (PCI-S).
Methods Post-hoc analysis from the Atrial Fibrillation 
Undergoing Coronary Artery Stenting (AFCAS) registry. 
Poor oral anticoagulation control was defined as time in 
therapeutic range (TTR) <65%, while impaired renal func-
tion as creatinine clearance (CrCl) <60 ml/min.
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[3]. Conversely, treatment with OAC confers a degree of 
bleeding risk [4].
Despite the introduction of non-vitamin K antagonist 
oral anticoagulants (NOACs), the vitamin K antagonist 
(VKA) is still widely used [5, 6]. Quality of OAC control, 
expressed as time in therapeutic range (TTR), is essential 
for optimal efficacy and safety [7]. Indeed, low TTR is sig-
nificantly associated with higher stroke and bleeding rates 
[8]. Another significant factor influencing morbidity and 
mortality in AF patients is renal impairment, which itself is 
associated with higher thromboembolic and bleeding risks 
compared to those with normal renal function [9]. Of note, 
renal impairment can significantly influence TTR and its 
impact on major adverse events [10].
AF patients commonly have associated coronary artery 
disease, and may undergo percutaneous coronary interven-
tion and stent (PCI-S) [3]. Such patients represent a par-
ticularly high-risk group for thromboembolism and bleed-
ing, especially with the necessity to combine OAC with 
antiplatelet therapy [11]. We, therefore, hypothesized a 
synergic impact of poor TTR and renal impairment in 
determining adverse outcomes (MACCE, bleeding) in AF 
patients. We tested this hypothesis in a post-hoc analysis 
from the Atrial Fibrillation Undergoing Coronary Artery 
Stenting (AFCAS) registry.
Methods
AFCAS was a prospective multicentre European regis-
try including AF patients undergoing PCI-S. Baseline and 
1 year outcomes from AFCAS have previously been pub-
lished [12, 13]. In brief, all patients with on-going or his-
tory of AF referred for a PCI-S procedure were eligible to 
take part in the study. A 12-month follow-up observation 
period was planned to record all major adverse outcomes. 
Ethic approval and written informed consent was obtained 
from every patient, and the study protocol conforms to the 
1975 Declaration of Helsinki. For this study, all patients 
that were prescribed with VKA and had TTR and data 
about renal function available were considered eligible for 
this ancillary analysis.
Thromboembolic risk was categorized according to 
 CHA2DS2-VASc score [14]. “Low-risk” patients were 
defined as males with a  CHA2DS2-VASc = 0 or females 
with  CHA2DS2-VASc = 1; “moderate risk” was defined as 
male patients with  CHA2DS2-VASc = 1; and “high risk” 
with  CHA2DS2-VASc ≥2.
TTR was calculated according to the Rosendaal inter-
polation method [15]. INR considered for TTR calculation 
were performed at baseline and, subsequently at every fol-
low-up visits (1, 3, 6, 12 months), when performed on-site. 
Poor anticoagulation control was defined as TTR <65%, 
consistent with previous studies [16, 17]. Renal func-
tion was evaluated according to CrCl calculated with the 
four-item Cockroft–Gault formula [(140−age) × (weight 
in kg) × (0.85 if female)/(72 × creatinine)]. Accordingly, 
an estimated CrCl level of <60 ml/min was used to define 
impaired renal function, again based on established guide-
lines [18].
Based on the original protocol, the principal efficacy 
outcome was a composite of MACCE, including acute MI, 
target vessel revascularization, stroke/transient ischemic 
attack (TIA), systemic embolic event, stent thrombosis 
and cardiovascular death. Acute MI was defined according 
to the universal definition in use at the time of the study 
[19]. Target vessel revascularization was defined as PCI-S 
or coronary bypass surgery in the previously treated vessel. 
Stent thrombosis was defined according to the Academic 
Research Consortium classification and included definite 
and probable events [20]. TIA was defined as a focal, tran-
sient (<24 h) neurological deficit adjudicated by a neurolo-
gist, whereas stroke was defined as a permanent, focal, neu-
rological deficit adjudicated by a neurologist and confirmed 
by computed tomography/magnetic resonance imag-
ing. Systemic embolism was defined as signs/symptoms 
of peripheral ischemia associated or not with a positive 
imaging test. Cardiovascular death was defined as a death 
related to cardiac cause or stroke. The principal safety out-
comes were ‘major bleeding’, defined as intracranial bleed-
ing, bleeding requiring blood transfusion or surgical/endo-
scopic treatment or leading to long-term disability or death.
Statistical analysis
Continuous variables were reported as median [IQR] 
and differences between subgroups were assessed with 
Kruskal–Wallis one-way ANOVA test with pairwise com-
parisons between groups. Categorical variables, expressed 
as counts and percentages, were analysed by Chi-squared 
test.
Differences in survival between groups were examined 
with log-rank test and Kaplan–Meier curves were drafted 
accordingly. Cox regression analysis, adjusted for age, sex, 
type of AF,  CHA2DS2-VASc score and antithrombotic 
therapy pattern at discharge, was performed to establish the 
relationship between TTR, CrCl and their synergic effect 
in determining MACCE during follow-up observation. A 
two-sided p value <0.05 was considered statistically sig-
nificant. The sensitivity and specificity of using TTR <65% 
and CrCl <60 ml/min alone or the combination of both was 
performed, to identify those AF patients undergoing PCI-S 
who are more likely to have a major adverse event during 
follow-up. All analyses were performed using SPSS v. 22.0 
(IBM, NY, USA).
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Results
Among 963 patients enrolled in the study original cohort, 
448 (46.5%) were eligible for this post-hoc ancillary anal-
ysis. Of these 125 (27.9%) had a TTR <65% only (Group 
I), 86 (19.2%) had a CrCl <60  ml/min only (Group II), 
while 62 (13.8%) had both conditions, i.e., TTR <65% 
andCrCl <60  ml/min (Group III). Conversely, 175 
(39.1%) patients had none of the two criteria (Group IV).
Baseline conditions are shown in Table 1. Patients in 
Groups II and III were older (p < 0.001) and more likely 
female (p < 0.001), and had lower BMI compared to 
those in Group I and IV (p < 0.001). Except for propor-
tion of patients with diabetes mellitus, that was higher in 
Group I (p = 0.025), baseline characteristics were similar 
across the four groups. Given the difference in age and 
proportion of female patients, the mean  CHA2DS2-VASc 
score was higher in Groups II and III (p < 0.001), as 
was the proportion with high thromboembolic risk 
 (CHA2DS2-VASc ≥2) (p < 0.001). No significant differ-
ences were found in the prescription (p = 0.867) or dura-
tion (p = 0.215) of antithrombotic therapy across the four 
groups (Table 1).
Follow-up
After a median [IQR] follow-up time of 359 
[342–369]  days, a total of 76 (17.0%) MACCE and 24 
(5.4%) major bleeding events were recorded, with an over-
all incidence of 18.7 per 100 patient-years and 5.7 per 100 
patient-years, respectively. Comparing the four subgroups, 
Group III had a higher MACCE rate compared to other 
groups (p = 0.007) [Fig. 1, Left Side]. For major bleeding 
events, Groups I and III had higher event rates compared to 
other groups (p = 0.006) [Fig. 1, right side]. Details about 
individual MACCE are reported in Table S1. A significant 
higher rate of cardiovascular death was found in Group III 
(p < 0.001) compared to other groups.
Kaplan–Meier analyses showed that when both condi-
tions were present (Group III) there was a higher risk for 
MACCE (og rank: 14.046, p = 0.003) compared to other 
groups [Fig.  2, Panel a]. TTR <65% alone (Group I) and 
both conditions together (Group III) had higher risk for 
major bleeding (log rank: 12.290, p = 0.006) [Fig. 2, Panel 
b].
On Cox regression analysis (Table  2), the presence of 
both conditions (i.e., TTR <65% and CrCl <60  ml/min) 
independently increased MACCE risk (p = 0.001), while 
TTR <65% and the presence of both conditions (i.e., 
TTR <65% and CrCl <60  ml/min) were independently 
associated with major bleeding (p = 0.004 and p = 0.028, 
respectively).
Sensitivity and specificity
For MACCE occurrence, TTR <65% had a sensitivity of 
50.0% (95% CI: 38.3–61.7%) and specificity of 60.0% (95% 
CI: 54.8–65.0%). CrCl <60  ml/min had a sensitivity of 
43.4% (95% CI: 32.1–55.3%) and specificity of 69.1% (95% 
CI: 64.1–73.8%). The combination had a higher specificity 
(88.7%, 95% CI: 85.1–91.7%), but lower sensitivity (26.3%, 
95% CI: 16.9–37.7%).
For major bleeding occurrence, the combination had low 
sensitivity (20.8%, 95% CI: 7.1–42.2%) but high specific-
ity (86.6%, 95% CI: 82.9–89.7%), compared to TTR <65% 
only (sensitivity 75.0%, 95% CI: 53.3–90.2%; specific-
ity 60.1%, 95% CI: 55.3–64.8%) or CrCl <60 ml/min only 
(sensitivity 33.3%, 95% CI: 15.6–55.3%; specificity 67.0%, 
95% CI: 62.3–71.4%).
Discussion
In this post-hoc ancillary analysis from the AFCAS study, 
our main finding was that the concomitant presence of both 
poor OAC control (TTR <65%) and impaired renal func-
tion (CrCl <60 ml/min) independently increased the occur-
rence of MACCE. For major bleeding, the presence of both 
conditions was again an independent risk factor, while 
poor OAC control per se was an independent risk factor for 
major bleeding, but not renal impairment. Using poor anti-
coagulation control and impaired renal function in combi-
nation would help identify AF patients undergoing PCI-S 
who are at risk of having a MACCE and/or a major bleed-
ing event during follow-up.
The relationship between renal impairment and adverse 
events in AF patients has been well-established [9]. Sev-
eral pathophysiological mechanisms have been proposed 
in determining the higher thromboembolic and bleeding 
risks in AF patients with chronic kidney disease (CKD) 
[9]. More recent evidence shows how progressive worsen-
ing of renal function is associated with changes in fibrin 
clot structure, leading to a progressive higher clot density 
[21]. Unsurprisingly, epidemiological and clinical trial data 
clearly demonstrate that in AF patients, CKD increases the 
risk of stroke [10, 22–26]. Indeed, “impaired renal func-
tion” was proposed to increase the predictive ability of 
stroke risk prediction scoring schemes in a highly selected 
anticoagulated trial cohort [27]. Despite a modest statistical 
improvement in predictive ability of clinical scores in the 
original derivation cohort, this approach was not validated 
in large “real-world” independent cohorts of AF patients 
[28, 29].
A recent meta-analysis provides evidence that warfa-
rin treatment reduces the risk of thromboembolic events 
in AF patients with CKD [hazard ratio (HR): 0.39, 95% 
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Table 1  Baseline characteristics of study cohort




min, n = 86
Group III Both 
conditions, n = 62
Group IV Nei-
ther TTR < 65% or 
CrCl < 60 ml/min, 
n = 175
p
Age, (years) median [IQR] 72 [66–75]a 79 [74–83]b 78 [74–80]b 71 [63–77]a <0.001
Female, n (%) 29 (23.2) 38 (44.2) 23 (37.1) 35 (20.0) <0.001
BMI, (kg/m2) median [IQR] 433 29 [26–32]a 25 [23–28]b 26 [24–29]b 29 [26–31]a <0.001
CrCl, (ml/min) median [IQR] 80.9 [69.6–109.0]a 48.5 [39.9–
55.0]b
46.3 [35.1–51.7]b 84.3 [70.8–106.3]a <0.001
TTR, (%) median [IQR] 37.4 [16.1–50.0]b 92.7 [81.0–100]a 37.7 [8.2–53.7]b 98.9 [86.2–100]a <0.001
AF Type, n (%) 444 0.531
 Paroxysmal 39 (31.7) 29 (34.1) 16 (25.8) 42 (24.1)
 Persistent 13 (10.6) 5 (5.9) 7 (11.3) 18 (10.3)
 Permanent 71 (57.7) 51 (60.0) 39 (62.9) 114 (65.5)
Hypertension, n (%) 101 (80.8) 71 (82.6) 52 (83.9) 132 (75.4) 0.373
Hypercholesterolemia, n (%) 81 (64.8) 53 (61.6) 40 (64.5) 120 (68.6) 0.716
Diabetes mellitus, n (%) 52 (41.6) 24 (27.9) 18 (29.0) 45 (25.7) 0.025
Smoking habit, n (%) 14 (11.2) 4 (4.7) 4 (6.5) 15 (8.6) 0.363
Previous coronary artery disease, n (%) 45 (36.0) 31 (36.0) 23 (37.1) 56 (32.0) 0.830
Previous MI, n (%) 35 (28.0) 24 (27.9) 17 (27.4) 35 (20.0) 0.318
Previous PCI, n (%) 19 (15.2) 10 (11.6) 7 (11.3) 23 (13.1) 0.844
Previous CABG, n (%) 21 (16.8) 12 (14.0) 15 (24.2) 28 (16.0) 0.396
Chronic heart failure, n (%) 26 (20.8) 19 (22.1) 13 (21.0) 26 (14.9) 0.405
Ejection fraction, (%) median [IQR] 323 50 [40–60] 50 [40–58] 50 [40–60] 51 [40–60] 0.507
Previous stroke/TIA, n (%) 20 (16.0) 19 (22.1) 13 (21.0) 36 (20.6) 0.672
Previous bleeding, n (%) 5 (4.0) 4 (4.7) 1 (1.6) 10 (5.7) 0.595
CHA2DS2-VASc, median [IQR] 3 [2–5]
a 4 [3–5]b 4 [3–5]b 3 [2–4]a <0.001
Thromboembolic risk, n (%) <0.001
 Low risk 0 (0) 0 (0) 0 (0) 5 (2.9)
 Moderate risk 11 (8.8) 0 (0) 0 (0) 24 (13.7)
 High risk 114 (91.2) 86 (100.0) 62 (100.0) 146 (83.4)
PCI clinical indication, n (%)
 Stable angina 59 (47.2) 31 (36.0) 25 (41.0) 91 (52.0)
 NSTE-ACS 43 (34.4) 34 (39.5) 27 (44.3) 62 (35.4)
 STEMI 15 (12.0) 17 (19.8) 8 (13.1) 14 (8.0) 0.137
 Other 8 (6.4) 4 (4.7) 1 (1.6) 8 (4.6)
PCI clinical setting, n (%) 0.158
 Emergency 63 (50.4) 34 (39.5) 29 (46.8) 99 (56.6)
 Urgency 44 (35.2) 38 (44.2) 25 (40.3) 62 (35.4)
 Elective 18 (14.4) 14 (16.3) 8 (12.9) 14 (8.0)
No diseased vessels, median [IQR] 447 2 [1–3] 2 [1–3] 2 [1–3] 2 [1–3] 0.684
No treated vessels, median [IQR] 1 [1–1]a 1 [1–1]a 1 [1–1]a 1 [1–1]a 0.049
Lesion severity, n (%) 414 0.080
 A 23 (20.9) 8 (10.3) 8 (14.8) 24 (14.0)
 B1/B2 68 (61.8) 59 (75.6) 32 (59.3) 103 (59.9)
 C 19 (17.3) 11 (14.1) 14 (25.9) 45 (26.2)
Complete revascularization, n (%) 440 60 (49.6) 35 (40.7) 24 (40.7) 89 (51.1) 0.280
Stent type, n (%) 434 0.196
 DES 28 (23.7) 14 (16.9) 19 (30.6)# 44 (25.7)
 Bioactive 16 (13.6) 15 (18.1) 10 (16.1)# 42 (24.6)
 BMS 70 (59.3) 49 (59.0) 31 (50.0)# 78 (45.6)
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confidence interval (CI): 0.18–0.86, p < 0.00001] [30]. 
Indeed, Bonde et  al. report a significant net clinical 
benefit for VKA amogst CKD patients at a high risk 
of thromboembolic events  (CHA2DS2-VASc ≥2) [25]. 
Paradoxically, a higher bleeding risk has also been 
reported in AF CKD patients [31, 32].
VKA treatment is effective and safe when there is good 
quality OAC control [7]. A European Society of Cardiol-
ogy Anticoagulation Task Force consensus statement 
a, b Differences in superscripts between the groups is related to significant differences in pairwise comparisons between groups
ACS acute coronary syndrome, AF atrial fibrillation, BMS bare metal stent, CABG coronary artery by-pass graft, CrCl creatinine clearance, 
DES drug eluting stent, IQR interquartile range, MI myocardial infarction, NSTE non ST elevation, PCI percutaneous coronary intervention, 
STEMI ST elevation myocardial infarction, TIA transient ischemic attack, TTR time in therapeutic range
# Total percentage is equal to 99.9% due to rounded figures
Table 1  (continued)




min, n = 86
Group III Both 
conditions, n = 62
Group IV Nei-
ther TTR < 65% or 
CrCl < 60 ml/min, 
n = 175
p
 Other 4 (3.4) 5 (6.0) 2 (3.2)# 7 (4.1)
Prescribed antithrombotic therapy, n (%) 0.867
 Single AP + VKA 14 (11.2) 9 (10.5) 7 (11.3) 15 (8.6)
 Dual AP + VKA 111 (88.8) 77 (89.5) 55 (88.7) 160 (91.4)
Antithrombotic therapy duration, n (%) 0.215
 0–3 months 66 (52.8) 50 (58.1)# 30 (48.4) 83 (47.4)#
 3–6 months 21 (16.8) 21 (24.4)# 11 (17.7) 41 (23.4)#
 ≥6 months 38 (30.4) 15 (17.4)# 21 (33.9) 51 (29.1)#
Fig. 1  Major adverse events rates according to presence of low-quality anticoagulation and moderate renal impairment. CrCl creatinine clear-
ance, MACCE major adverse coronary and cerebrovascular events, TTR time in therapeutic range
 Clin Res Cardiol
1 3
recommends that good anticoagulation control is defined as 
a TTR >70% [33]. Indeed, lower TTR values are associated 
with higher risks of thromboembolic and bleeding  events 
[8, 17, 34, 35].
A relationship between quality of OAC control and 
renal impairment has been reported. For example, an 
analysis coming from the Outcomes Registry for Better 
Informed Treatment of Atrial Fibrillation (ORBIT-AF) 
registry found that the presence of CKD was significantly 
associated with a low TTR [36]. In a post-hoc analy-
sis from the Stroke Prevention using an Oral Thrombin 
Inhibitor in patients with atrial Fibrillation (SPORTIF) 
III and V trials, there was a significant linear relationship 
between CrCl (expressed with Cockroft–Gault equation) 
and TTR [10]. Furthermore, the presence of CKD could 
modify the relationship between TTR and risk for both 
stroke and major bleeding, conferring a higher risk even 
with the same level of anticoagulation control [10].
The role of renal impairment in determining adverse 
outcomes amongst patients undergoing PCI-S has been 
demonstrated in general populations, both in terms of 
major cardiovascular events [37] and major bleeding [38]. 
Similar data have been already described in patients with 
AF receiving PCI-S [39]. The present study results, in the 
context of the available evidence, reinforces the concept 
that quality of OAC control and renal impairment are 
strongly interconnected in determining the occurrence of 
major adverse outcomes in AF patients undergoing PCI-
S. Our study also reinforces the importance of good qual-
ity OAC control in determining major bleeding amongst 
patients with renal impairment, at least in this specific 
clinical scenario.
Limitations
Main limitation to this study is its post-hoc observational 
nature. The relatively small numbers of patients and the 
lack of NOAC data could limit the generalizability of the 
results to contemporary clinical practice.
In conclusion, there was a synergic impact of OAC 
control and renal function in determining major adverse 
events (MACCE and major bleeding) in AF patients 
undergoing PCI-S. Use of poor anticoagulation control 
and impaired renal function in combination would help 
identify AF patients undergoing PCI-S who are at risk of 
MACCE and/or major bleeding.
Fig. 2  Kaplan–Meier curves for major adverse events. Panel (a) 
MACCE; panel (b) major bleeding. Large dashes Group I, Narrow 
dashes Group II, Solid line Group III, Alternate dashes Group IV, 
CrCl creatinine clearance, MACCE major adverse coronary and cer-
ebrovascular events, TTR time in therapeutic range
Table 2  Cox regression analysis for major adverse events
Adjusted for age, sex, type of AF,  CHA2DS2-VASc score, antithrom-
botic therapy
CI confidence interval, CrCl creatinine clearance, HR hazard ratio, 
TTR time in therapeutic range
HR 95% CI p
MACCE
 TTR <65% 1.04 0.57–1.91 0.896
 CrCl <60 ml/min 1.10 0.56–2.16 0.776
 Both conditions 2.62 1.46–4.72 0.001
 None condition (reference) – – –
Major bleeding event
 TTR <65% 6.24 1.83–22.58 0.004
 CrCl <60 ml/min 2.26 0.45–11.26 0.318
 Both conditions 4.96 1.18–20.78 0.028
 None condition (reference) – – –
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